ChromaDex (NASDAQ:CDXC - Get Free Report) posted its earnings results on Thursday. The company reported $0.02 EPS for the quarter, Zacks reports. The business had revenue of $25.58 million for the quarter, compared to analysts' expectations of $23.70 million. ChromaDex had a return on equity of 5.06% and a net margin of 1.62%. During the same quarter in the previous year, the firm earned ($0.01) earnings per share. ChromaDex updated its FY 2024 guidance to EPS.
ChromaDex Trading Up 67.9 %
Shares of NASDAQ CDXC traded up $2.37 during midday trading on Friday, reaching $5.86. 37,543,352 shares of the company were exchanged, compared to its average volume of 264,220. The stock has a fifty day simple moving average of $3.53 and a 200 day simple moving average of $3.23. The stock has a market cap of $444.95 million, a P/E ratio of 586.59 and a beta of 1.88. ChromaDex has a 1 year low of $1.32 and a 1 year high of $5.98.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a "buy" rating and issued a $6.00 target price on shares of ChromaDex in a report on Friday, August 9th.
View Our Latest Stock Analysis on CDXC
Insiders Place Their Bets
In other ChromaDex news, Director Kristin Patrick sold 23,000 shares of ChromaDex stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $3.57, for a total value of $82,110.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 9.64% of the stock is owned by insiders.
ChromaDex Company Profile
(
Get Free Report)
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Featured Articles
Before you consider ChromaDex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ChromaDex wasn't on the list.
While ChromaDex currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.